Serum PDGF-AB in Pleural Mesothelioma

Overexpression of platelet-derived growth factor (PDGF) has been observed in lung and pleural tumors. The aim of this study was to evaluate the diagnostic and prognostic role of serum PDGF in pleural mesothelioma (PM). Four groups of subjects were studied: 93 malignant PM patients, 33 primary non sm...

Full description

Saved in:
Bibliographic Details
Published in:Tumor biology 2005-09, Vol.26 (5), p.221-226
Main Authors: Filiberti, Rosa, Marroni, Paola, Neri, Monica, Ardizzoni, Andrea, Betta, Pier Giacomo, Cafferata, Mara A., Canessa, Pier Aldo, Puntoni, Riccardo, Ivaldi, Giovanni Paolo, Paganuzzi, Michela
Format: Article
Language:English
Subjects:
Age Factors
Aged
Aged, 80 and over
Biomarkers, Tumor - blood
Case-Control Studies
Female
Humans
Lung Neoplasms - pathology
Male
Mesothelioma - pathology
Middle Aged
Platelet-Derived Growth Factor - analysis
Pleural Neoplasms - pathology
Prognosis
Research Article
Risk Factors
Sex Factors
Survival Analysis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Overexpression of platelet-derived growth factor (PDGF) has been observed in lung and pleural tumors. The aim of this study was to evaluate the diagnostic and prognostic role of serum PDGF in pleural mesothelioma (PM). Four groups of subjects were studied: 93 malignant PM patients, 33 primary non small cell lung cancer patients, 51 subjects exposed to asbestos, defined as high-risk controls, and 24 healthy controls. PDGF-AB mean concentration was higher in PM patients (45.8 ng/ml) than in high-risk controls (33.1 ng/ml) and healthy controls (26.8 ng/ml). Using the cut-off level of 49.8 ng/ml, corresponding to the mean + 2SD of PDGF-AB in healthy controls, 43% of PM patients showed positive PDGF-AB levels. Survival was evaluated in 82 PM patients. At the end of the follow-up (median 9.8 months) 80.5% of patients had died. Median survival was 13.1 and 7.9 months for patients with PDGF-AB lower and higher than the cut-off, respectively. Adjusting for age, sex, histology and platelet count, positive PDGF-AB levels were associated with lower survival (OR = 1.2, 95%CI: 0.9–1.6), even if not significantly so. In conclusion, serum PDGF may represent a useful additional parameter to prognostic factors already available for PM.
ISSN:1010-4283
1423-0380
DOI:10.1159/000087376